Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 6Leukemia 6Blast Crisis 5Sarcoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Accelerated Phase 3Carcinoma, Ovarian Epithelial 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Meningioma 2Melanoma 2Leukemia, Biphenotypic, Acute 2Fibrosarcoma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Seminoma 1Sarcoma, Synovial 1

Interventions

Doxorubicin 4pazopanib 2Radiotherapy 2Ifosfamide 2saracatinib 1sapanisertib 1peposertib 1liposomal doxorubicin 1cixutumumab 1Specimen Handling 1Radiation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1MLN 8237 1Imatinib Mesylate 1HhAntag691 1Chemotherapy, Adjuvant 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Dermatofibrosarcoma × Imatinib Mesylate × Clear all
NCT00084630 2013-02-28

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Sarcoma

Fibrosarcoma, Sarcoma, Dermatofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡